---
title: "AlzeCure swings to Q2 FY26 profit of SEK 80.18 million; net sales rise to SEK 97.33 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296993783.md"
description: "AlzeCure Pharma reported a Q2 FY26 profit of SEK 80.18 million, swinging from a prior-year loss, with net sales rising to SEK 97.33 million. Basic EPS turned positive at SEK 0.7. The company signed out-licensing deals with Eli Lilly and QuantumCell, valued over USD 3.2 billion, receiving USD 22 million upfront in August."
datetime: "2026-08-26T06:07:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296993783.md)
  - [en](https://longbridge.com/en/news/296993783.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296993783.md)
generator: "portal-rs"
---

# AlzeCure swings to Q2 FY26 profit of SEK 80.18 million; net sales rise to SEK 97.33 million

-   AlzeCure Pharma released Q2 results with net sales of SEK 97.33 million, compared with no revenue a year earlier. \* Earnings swung to SEK 80.18 million from a loss of SEK 9.76 million; basic EPS turned positive to SEK 0.7 from -SEK 0.11. \* Operating cash flow widened to an outflow of SEK 19.19 million from SEK 7.98 million, while cash totaled SEK 13.49 million. \* For H1, net sales were SEK 97.33 million; earnings swung to SEK 58.49 million from a loss of SEK 19.89 million. \* Signed out-licensing deals with Eli Lilly and QuantumCell, carrying potential value above USD 3.2 billion excluding royalties; received USD 22 million upfront in August. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzeCure Pharma AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)

## Related News & Research

- [Is Eli Lilly Stock Outperforming the Dow?](https://longbridge.com/en/news/297309786.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)
- [BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million](https://longbridge.com/en/news/296992922.md)
- [Lilly's $9.94 Billion Mounjaro Franchise Wins a Heart-Risk Label](https://longbridge.com/en/news/297356212.md)
- [Evolve Private Wealth LLC Lowers Stock Holdings in Eli Lilly and Company $LLY](https://longbridge.com/en/news/297282696.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**